Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 5.53B |
| Revenue (ttm) | 59.56M |
| Net Income (ttm) | -162.45M |
| Shares Out | 784.69M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | 11.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,845,435 |
| Average Volume | 3,320,083 |
| Open | 7.14 |
| Previous Close | 7.14 |
| Day's Range | 6.90 - 7.20 |
| 52-Week Range | 3.31 - 11.80 |
| Beta | 0.43 |
| RSI | 46.16 |
| Earnings Date | May 29, 2026 |
About HKG:1167
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C re... [Read more]
Financial Performance
In 2025, HKG:1167's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
BEIJING, SHANGHAI and BOSTON , Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E7...
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
BEIJING and SHANGHAI and BOSTON , Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered...
Jacobio Pharma Announces 2025 Interim Results
BEIJING and SHANGHAI and BOSTON , Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025. During the reporting period, the Co...
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
BEIJING, SHANGHAI and BOSTON , July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB...